ABSTRACT

Introduction: Many men diagnosed with prostate cancer are concerned with how the disease and its course of treatment could affect their health-related quality of life (HRQOL). To aid in the decision-making process on a course of treatment and to better understand how these treatments can affect HRQOL, knowledge of pretreatment HRQOL is essential.

Aims: To assess the racial and ethnic variations in HRQOL scores in men newly diagnosed with prostate cancer before elected a course of treatment.

Methods: Male members of the Kaiser Permanente of Southern California health plan who were newly diagnosed with prostate cancer completed the five-domain specific Expanded Prostate Index Composite–26 (EPIC-26) HRQOL questionnaire from March 1, 2011 through August 31, 2013 (N = 2,579). Domain scores were compared across racial and ethnic subgroups and multiple logistic regression analyses were used to assess the association after adjusting for sociodemographic and clinical characteristics.

Main Outcome Measures: The five EPIC-26 domain scores (sexual, bowel, hormonal, urinary incontinence, and urinary irritation and obstruction).

Results: Results from the fully adjusted analyses indicated that non-Hispanic black men were more likely to be above the sample median on the sexual (odds ratio [OR] = 1.43, 95% CI = 1.09–1.88), hormonal (OR = 1.35, 95% CI = 1.03–1.77), and urinary irritation and obstruction (OR = 1.34, 95% CI = 1.03–1.74) domains compared with non-Hispanic white men. The Asian or Pacific Islander men were less likely to be above the sample median on the sexual domain (OR = 0.60, 95% CI = 0.44–0.83) compared with non-Hispanic white men. No additional statistically significant differences were identified.

Conclusions: Within an integrated health care organization, we found minimal racial and ethnic differences, aside from sexual function, in pretreatment HRQOL in men newly diagnosed with prostate cancer. These findings provide important insight with which to interpret HRQOL changes in men newly diagnosed with prostate cancer during and after prostate cancer treatment. Reading SR, Porter KR, Slezak JM, et al. Racial and Ethnic Variation in Health-Related Quality of Life Scores Prior to Prostate Cancer Treatment. Sex Med 2017;5:e219–e228.

Copyright © 2017, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Key Words: EPIC-26; Ethnicity; Prostate Cancer; Quality of Life; Questionnaire; Race
INTRODUCTION

Prostate cancer is the most prevalent type of solid tumor malignancy and the most common type of cancer diagnosis in American men. Fortunately, the survival rate for men diagnosed with prostate cancer is relatively high. Nearly 100% of men are alive at 5 years, 99% are alive at 10 years, and 94% are alive at 15 years, with prostate cancer survivors representing one in five of all living cancer survivors. This high likelihood of prostate cancer survival has created a shift in focus from that of basic survival to improvement or sustainment of health-related quality of life (HRQOL), because many men diagnosed with prostate cancer have reported disease-specific functional deterioration (eg, decreased urinary, sexual and bowel function) and broader HRQOL concerns (eg, decreased overall energy and vitality and lower performance in physical and social roles) associated with undergoing prostate cancer treatment. Thus, of primary concern for many men diagnosed with prostate cancer is how the disease and its course of treatment could affect their HRQOL.

Unfortunately, there is limited information regarding HRQOL differences in men diagnosed with prostate cancer before electing a course of prostate cancer treatment. Comparisons have been made between pre- and post-treatment HRQOL after specific prostate cancer treatments, and in the long-term changes in HRQOL during the post-treatment survivorship period, and in the use of HRQOL as a prognostic tool for survival. However, these comparisons have not been made within population subgroups. Broad descriptive pretreatment HRQOL information also has been reported, but not within population subgroups. Specifically, sparse data are available on HRQOL for men who identify as Hispanic or Asian and Pacific Islander. Given the growing number of racial and ethnic minorities contributing to the population of prostate cancer survivors, identifying potential differences between these groups could aid the patient-provider decision-making process when electing a course of prostate cancer care. Accordingly, our aim in the present investigation was to assess the racial and ethnic variations in pretreatment HRQOL in men newly diagnosed with prostate cancer to help identify those men who might be more likely to have poor pretreatment HRQOL.

METHODS

Setting

The source population included male members of the Kaiser Permanente of Southern California (KPSC) health plan, a not-for-profit integrated health care delivery system that provides comprehensive care to more than 4 million individuals throughout the southern California region. Membership within the KPSC is socially and demographically diverse and highly representative of the underlying population. Individuals are enrolled in the KPSC health plan through their employer, family member, individually, or a state or federally funded program. All individual-level data, including sociodemographic information and details of medical care obtained from outpatient, emergency department, and hospital encounters, are captured within a comprehensive electronic health record based on the EpicCare system (Epic Systems, Verona, WI, USA).

Study Population

The present investigation included male KPSC members who (i) received an incident positive prostate biopsy diagnosis from a KPSC medical center from March 1, 2011 through August 31, 2013 and (ii) were willing to participate in a study to evaluate prostate cancer treatment outcomes (n = 5,727; Figure 1). Participation was restricted to include only those men who completed a pretreatment HRQOL questionnaire within a 90-day window of their prostate biopsy diagnosis (60%; n = 3,422). This 90-day window started 30 days before and ended 60 days after prostate biopsy diagnosis to allow men to be included who (i) completed the questionnaire on the date of their prostate biopsy appointment but then had their prostate biopsy rescheduled and (ii) did not complete the questionnaire on the date of their prostate biopsy appointment so instead had the questionnaire mailed to their home. Most men completed the questionnaire in a KPSC clinic before undergoing their prostate biopsy examination (79%; n = 2,702), with the remainder completing the questionnaire by mail. If a completed pretreatment HRQOL questionnaire had not been returned by mail within 1 month of the man undergoing his prostate biopsy, he was mailed an additional questionnaire to complete and return by mail.

Men who were missing data to assess their sociodemographic (age, race and ethnicity, marital status, neighborhood education, neighborhood income, and primary language), health status (body mass index [BMI] and tobacco use), and medical history (Charlson Comorbidity Index [CCI] score, Gleason score, prostate cancer family history, serum prostate-specific antigen [PSA] level, and knowledge of prostate cancer status at time of questionnaire completion) information were excluded. The analytic cohort included 2,579 men. This investigation was approved by the KPSC’s institutional review board and the informed consent requirement was waived, citing that the pretreatment HRQOL questionnaire was considered part of standard urologic care. There was no remuneration for participation.

Health-Related Quality of Life

Pretreatment HRQOL was assessed with the Expanded Prostate Cancer Index Composite Short Form (EPIC-26) questionnaire, an abbreviated version of the full-length EPIC-50. This validated and self-administered 26-item questionnaire, specifically designed for individuals diagnosed with prostate cancer, evaluated five prostate cancer-specific functional and bother domains: (i) sexual, (ii) bowel, (iii) hormonal, (iv) urinary incontinence, and (v) urinary irritation and obstruction. Response options for each item form a Likert scale and multiple-item scale scores are transformed linearly to a 0 to 100 domain scale, with higher scores indicating better HRQOL and a
minimum of 80% item completion being necessary to generate a domain score. A certified Spanish translator was employed to create a Spanish version of the EPIC-26 questionnaire for use in the present investigation. All questionnaires were scanned and processed using Teleform (Cardiff Software, Inc, Vista CA, USA), a paper-based data capture software system.
Participant Characteristics

Age (years) was determined from the electronic health record calculated by subtracting the man’s date of birth from his date of prostate biopsy diagnosis. Race and ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, or non-Hispanic Asian or Pacific Islander), marital status (married or with a partner or not married and without a partner), primary language (English, Spanish, or other), BMI (<25, 25–29, or ≥30 kg/m²), tobacco use (current, former, or never), CCI score (0, 1, or ≥2; calculated using International Classification of Diseases, Ninth Revision, Clinical Modification codes from inpatient and outpatient encounters during the 1-year period before questionnaire completion, to adjust for severe chronic conditions and risk of mortality in the analyses⁴), family history of prostate cancer (yes or no), and serum PSA level (nanograms per milliliter) were obtained from the closest clinical encounter before prostate cancer diagnosis.

The percentage of the man’s neighborhood that completed high school and his neighborhood median household income were derived through geocoding by mapping the man’s home address to the US 2000 census block groups. Gleason scores were abstracted from electronic health record pathology reports using a KPSC-developed natural language processing program from closest clinical encounter before prostate cancer diagnosis. Serum PSA level (nanograms per milliliter) was used to verify the positive prostate biopsy result. We assumed that the man had knowledge of his prostate cancer status, at the time of questionnaire completion, if he completed the questionnaire by mail after his prostate biopsy diagnosis.

Statistical Analyses

Sociodemographic and clinical characteristics across each racial and ethnic subgroup were compared using χ² and non-parametric analysis of variance (Kruskal-Wallis) tests, as appropriate. EPIC-26 domain scores also were compared using Kruskal-Wallis tests. To assess the association of race and ethnicity with each of the EPIC-26 domain scores, multivariable logistic regression analyses were performed. Each EPIC-26 domain score was dichotomized at the median. Models were built sequentially, beginning with the crude analysis followed by inclusion of covariates for sociodemographics, health status, and then medical history. All analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC, USA).

RESULTS

Of the 2,579 men included in our investigative cohort, 1,260 (49%) were non-Hispanic white, 375 (15%) were non-Hispanic black, 692 (27%) were Hispanic, and 252 (10%) were non-Hispanic Asian or Pacific Islander (Table 1). The non-Hispanic white men were generally older (median = 66.0 years), more likely to have a larger percentage of their neighborhood that completed high school (median = 91.2%), and had a higher neighborhood household income (median = $71,562.5) compared with the other racial and ethnic subgroups. The non-Hispanic Asian or Pacific Islander men were the most likely to be married (86.1%) and had the lowest BMI (42.1% with BMI < 25 kg/m²), whereas non-Hispanic black men were the most likely to have the highest CCI score (40.0% with score ≥ 2) and have a family history of prostate cancer in addition to non-Hispanic white men (9.3% and 9.4%, respectively).

Most men reported high baseline levels of pretreatment HRQOL across four of the five EPIC-26 domains (bowel, hormonal, urinary incontinence, and urinary irritation and obstruction; median score range = 87.5–100; Table 2). However, low levels were reported on the sexual function domain (median score range = 50.0–62.5). Only 11.0% of men reported a score of 100 on this domain compared with the 33.8% to 66.1% of men who reported a score of 100 across the other four domains.

Median values for each of the EPIC-26 domains were 58.3 for the sexual domain, 100 for the bowel domain, 95.0 for the hormonal domain, 100 for the urinary incontinence domain, and 93.8 for the urinary irritation and obstruction domain. In the unadjusted models, compared with the non-Hispanic white men, non-Hispanic black men were more likely to be above the median on the sexual function (odds ratio [OR] = 1.34, 95% CI = 1.05–1.71) and urinary irritation and obstruction (OR = 1.46, 95% CI = 1.14–1.88) domains (Table 3). In addition, Hispanic men were more likely to be above the median on the urinary irritation and obstruction domain (OR = 1.30, 95% CI = 1.06–1.59) and the Asian or Pacific Islander men were more likely to be above the median on the hormonal domain (OR = 1.51, 95% CI = 1.10–2.07) and less likely to be above the median on the sexual function domain (OR = 0.69, 95% CI = 0.52–0.93) compared with non-Hispanic white men.

After adjustment for sociodemographics (age, marital status, neighborhood education, neighborhood income, and primary language), the non-Hispanic black men remained more likely to be above the median on the urinary irritation and obstruction domain (OR = 1.35, 95% CI = 1.04–1.74) and the Asian or Pacific Islander men remained more likely to be above the median on the hormonal domain (OR = 1.42, 95% CI = 1.03–1.96) and less likely to be above the median on the sexual function domain (OR = 0.66, 95% CI = 0.48–0.90). No other statistically significant differences were identified. Inclusion of health status measures (BMI and tobacco use) did not change the analytic findings, except for Asian or Pacific Islander men being less likely to be above the median on the urinary incontinence domain (OR = 0.73, 95% CI = 0.53–1.00) and no longer being more likely to be above the median on the hormonal domain (OR = 1.26, 95% CI = 0.91–1.74) compared with non-Hispanic white men.

After adjustment for medical history covariates (CCI score, Gleason score, family history of prostate cancer, serum PSA level,
Table 1. Participant sociodemographic and clinical characteristics by racial and ethnic subgroup membership (N = 2,579)

| Sociodemographics | Non-Hispanic white (n = 1,260; 48.9%) | Non-Hispanic black (n = 375; 14.5%) | Hispanic (n = 692; 26.8%) | Non-Hispanic Asian or Pacific Islander (n = 252; 9.8%) | P value* |
|--------------------|---------------------------------------|-------------------------------------|---------------------------|-----------------------------------------------------|---------|
| Age (y) | | | | | <.001 |
| Median | 66.0 | 63.0 | 63.0 | 65.0 |
| 25th–75th percentiles | 60.0–71.0 | 56.0–70.0 | 56.0–68.0 | 60.0–69.0 |
| Age group (y), n (%) | | | | | <.001 |
| ≤49 | 24 (26.7) | 22 (24.4) | 39 (43.3) | 5 (5.6) |
| 50–59 | 271 (40.7) | 108 (16.2) | 231 (34.7) | 56 (8.4) |
| 60–69 | 592 (50.8) | 147 (12.6) | 296 (25.4) | 130 (11.2) |
| ≥70 | 373 (56.7) | 98 (14.9) | 126 (19.2) | 61 (9.3) |
| Marital status, n (%) | | | | | .002 |
| Married or partner | 970 (48.2) | 277 (13.8) | 549 (27.3) | 217 (10.8) |
| Not married, no partner | 290 (51.2) | 98 (17.3) | 143 (25.3) | 35 (6.2) |
| Neighborhood completing high school, % | | | | | <.001 |
| Median | 91.2 | 83.1 | 75.6 | 88.6 |
| 25th–75th percentiles | 83.4–95.6 | 70.9–91.8 | 57.2–87.9 | 77.1–94.4 |
| Neighborhood household income ($) | | | | | <.001 |
| Median | 71,562.5 | 55,541.0 | 54,754.5 | 68,842.0 |
| 25th–75th percentiles | 52,435.0–93,264.0 | 40,758.0–78,425.0 | 40,511.0–70,708.5 | 53,001.5–85,118.5 |
| Primary language, n (%) | | | | | <.001 |
| English | 1,254 (55.4) | 375 (16.6) | 404 (17.9) | 230 (10.2) |
| Spanish | 0 (0.0) | 0 (0.0) | 287 (100.0) | 0 (0.0) |
| Other | 6 (20.7) | 0 (0.0) | 1 (3.5) | 22 (75.9) |
| Health status | | | | | |
| Body mass index (kg/m²), n (%) | | | | | <.001 |
| <25 | 266 (47.6) | 84 (15.0) | 103 (18.4) | 106 (19.0) |
| 25–29 | 585 (49.3) | 150 (12.7) | 334 (28.2) | 117 (9.9) |
| ≥30 | 409 (49.0) | 141 (16.9) | 255 (30.6) | 29 (3.5) |
| Tobacco use, n (%) | | | | | .126 |
| Current | 98 (45.2) | 38 (17.5) | 55 (25.4) | 26 (12.0) |
| Former | 511 (51.0) | 154 (15.4) | 252 (25.1) | 86 (8.6) |
| Never | 651 (47.9) | 183 (13.5) | 385 (28.3) | 140 (10.3) |
| Medical history | | | | | |
| Charlson comorbidity index, n (%) | | | | | <.001 |
| 0 | 649 (49.7) | 160 (12.2) | 386 (29.5) | 112 (8.6) |
| 1 | 203 (44.1) | 65 (14.1) | 128 (27.8) | 64 (13.9) |
| ≥2 | 408 (50.3) | 150 (18.5) | 178 (21.9) | 76 (9.4) |
| Gleason score, n (%) | | | | | .099 |
| ≤6 | 707 (47.6) | 208 (14.0) | 427 (28.7) | 144 (9.7) |
| 7 | 412 (52.4) | 117 (14.9) | 186 (23.6) | 72 (9.2) |
| ≥8 | 141 (46.1) | 50 (16.3) | 79 (25.8) | 36 (11.8) |
| Prostate cancer family history, n (%) | | | | | .005 |
| Yes | 119 (56.9) | 35 (16.8) | 46 (22.0) | 9 (4.3) |
| No | 1,141 (48.1) | 340 (14.4) | 646 (27.3) | 243 (10.3) |
| PSA levels at ASRRs (ng/mL)† | | | | | .426 |
| Age ≤ 49 y | | | | | |
| Median | 3.8 | 4.8 | 3.6 | 3.5 |

(continued)
and knowledge of prostate cancer status at time of questionnaire completion), non-Hispanic black men were more likely to be above the median on the sexual function (OR = 1.43, 95% CI = 1.09–1.88), hormonal (OR = 1.35, 95% CI = 1.03–1.77), and urinary irritation and obstruction (OR = 1.34 95% CI = 1.03, 1.74) domains compared with non-Hispanic white men. The Asian or Pacific Islander men also remained less likely to be above the median on the sexual function domain (OR = 0.60, 95% CI = 0.39–0.96).

### Table 1. Continued

| EPIC-26 domains                      | Non-Hispanic white (n = 1,260) | Non-Hispanic black (n = 375) | Hispanic (n = 692) | Non-Hispanic Asian or Pacific Islander (n = 252) | P value* |
|--------------------------------------|-------------------------------|-----------------------------|-------------------|-------------------------------------------------|---------|
| 25th–75th percentiles                | 3.4–5.5                       | 3.0–7.7                     | 2.8–5.3           | 2.7–4.6                                         | .422    |
| Age 50–59 y                          |                               |                             |                   |                                                 |         |
| Median                               | 4.8                           | 5.0                         | 4.9               | 5.4                                             |         |
| 25th–75th percentiles                | 4.0–6.5                       | 4.2–8.3                     | 3.9–6.9           | 4.0–6.5                                         | .161    |
| Age 60–69 y                          |                               |                             |                   |                                                 | .297    |
| Median                               | 6.1                           | 6.6                         | 6.1               | 6.1                                             |         |
| 25th–75th percentiles                | 5.0–8.1                       | 5.2–10.2                    | 5.0–8.8           | 5.0–8.6                                         | .297    |
| Age ≥ 70 y                           |                               |                             |                   |                                                 |         |
| Median                               | 8.8                           | 9.2                         | 9.3               | 7.7                                             |         |
| 25th–75th percentiles                | 6.8–13.5                      | 7.3–13.1                    | 6.7–13.5          | 6.2–11.6                                        |         |
| Knowledge of prostate cancer status, n (%) |                        |                             |                   |                                                 |         |
| Yes                                  | 260 (51.1)                    | 75 (14.7)                   | 132 (25.9)        | 42 (8.3)                                        | .503    |
| No                                   | 1,000 (48.3)                  | 300 (14.7)                  | 560 (27.1)        | 210 (10.1)                                      |         |

ASRRs = age-specific reference ranges; PSA = prostate-specific antigen.

*By Kruskal-Wallis and χ² tests.

†Increased PSA level per ASRR: 2.5 ng/mL at 40 to 49 years, 3.5 ng/mL at 50 to 59 years, 4.5 ng/mL at 60 to 69 years, and 6.5 ng/mL at 70 years and older.

### Table 2. Distribution of participant EPIC-26 domain scores by racial and ethnic subgroup membership (N = 2,579)

| EPIC-26 domains                      | Non-Hispanic white (n = 1,260) | Non-Hispanic black (n = 375) | Hispanic (n = 692) | Asian or Pacific Islander (n = 252) | P value* |
|--------------------------------------|-------------------------------|-----------------------------|-------------------|-----------------------------------|---------|
| Sexual (n = 2,355)                   | 1,164                         | 342                         | 628               | 221                               | .041    |
| Median                               |                               |                             |                   |                                   |         |
| 25th–75th percentiles                | 26.3–87.5                     | 34.7–87.5                   | 30.5–83.3         | 26.3–77.8                         |         |
| Range                                | 0.0–100.0                     | 0.0–100.0                   | 0.0–100.0         | 0.0–100.0                         |         |
| Bowel (n = 2,316)                    | 1,177                         | 331                         | 583               | 225                               | .156    |
| Median                               | 100.0                         | 100.0                       | 100.0             | 100.0                             |         |
| 25th–75th percentiles                | 95.8–100.0                    | 95.8–100.0                  | 91.7–100.0        | 95.8–100.0                        |         |
| Range                                | 16.7–100.0                    | 25.0–100.0                  | 20.8–100.0        | 0.0–100.0                         |         |
| Hormonal (n = 2,150)                 | 1,116                         | 304                         | 532               | 198                               | .668    |
| Median                               | 95.0                          | 95.0                        | 95.0              | 95.0                              |         |
| 25th–75th percentiles                | 85.0–100.0                    | 85.0–100.0                  | 81.3–100.0        | 85.0–100.0                        |         |
| Range                                | 18.8–100.0                    | 375–100.0                   | 6.3–100.0         | 0.0–100.0                         |         |
| Urinary incontinence (n = 2,310)     | 1,174                         | 321                         | 595               | 220                               | .154    |
| Median                               | 100.0                         | 100.0                       | 100.0             | 100.0                             |         |
| 25th–75th percentiles                | 85.5–100.0                    | 85.5–100.0                  | 85.5–100.0        | 79.3–100.0                        |         |
| Range                                | 22.8–100.0                    | 14.5–100.0                  | 0.0–100.0         | 25.0–100.0                        |         |
| Urinary irritation and obstruction (n = 2,239) | 1,149                       | 314                         | 556               | 220                               | .002    |
| Median                               | 87.5                          | 93.8                        | 93.8              | 93.8                              |         |
| 25th–75th percentiles                | 75.0–100.0                    | 81.3–100.0                  | 75.0–100.0        | 81.3–100.0                        |         |
| Range                                | 25.0–100.0                    | 6.3–100.0                   | 6.3–100.0         | 0.0–100.0                         |         |

EPIC-26 = Expanded Prostate Index Composite–26.

*By Kruskal-Wallis test.
Table 3. Multiple logistic regression analyses examining race and ethnicity as a predictor of each EPIC-26 domain score controlling for sociodemographic and clinical characteristics (n = 2,579)

|                      | Non-Hispanic White (n = 1,260) | Non-Hispanic Black (n = 375) | Hispanic (n = 692) | Asian or Pacific Islander (n = 252) |
|----------------------|---------------------------------|------------------------------|--------------------|-------------------------------------|
|                      | OR 95% CI                        | OR 95% CI                    | OR 95% CI          | OR 95% CI                           |
| **Crude**            |                                 |                              |                    |                                     |
| Sexual (n = 2,355)   | ref                             | 1.34 (1.05–1.71)             | 0.98 (0.81–1.20)   | 0.69 (0.52–0.93)                   |
| Bowel (n = 2,316)    | ref                             | 1.14 (0.88–1.47)             | 0.88 (0.71–1.08)   | 1.15 (0.85–1.55)                   |
| Hormonal (n = 2,150) | ref                             | 1.25 (0.97–1.62)             | 1.13 (0.92–1.40)   | 1.51 (1.10–2.07)                   |
| Urinary incontinence (n = 2,310) | ref | 0.91(0.70–1.19)  | 0.86 (0.70–1.06)   | 0.79 (0.58–1.06)                   |
| Urinary irritation and obstruction (n = 2,239) | ref | 1.46 (1.14–1.88) | 1.30 (1.06–1.59)   | 1.27 (0.95–1.69)                   |
| **Sociodemographics** |                                 |                              |                    |                                     |
| Sexual (n = 2,355)   | ref                             | 1.27 (0.97–1.65)             | 0.96 (0.75–1.23)   | 0.66 (0.48–0.90)                   |
| Bowel (n = 2,316)    | ref                             | 1.13 (0.87–1.48)             | 0.89 (0.70–1.13)   | 1.14 (0.83–1.55)                   |
| Hormonal (n = 2,150) | ref                             | 1.27 (0.97–1.66)             | 1.06 (0.83–1.36)   | 1.42 (1.03–1.96)                   |
| Urinary incontinence (n = 2,310) | ref | 0.89 (0.68–1.16) | 0.90 (0.70–1.16)   | 0.77 (0.57–1.05)                   |
| Urinary irritation and obstruction (n = 2,239) | ref | 1.35 (1.04–1.74) | 1.11 (0.87–1.41)   | 1.20 (0.90–1.62)                   |
| **Health status**    |                                 |                              |                    |                                     |
| Sexual (n = 2,355)   | ref                             | 1.28 (0.98–1.68)             | 0.96 (0.74–1.23)   | 0.57 (0.41–0.78)                   |
| Bowel (n = 2,316)    | ref                             | 1.13 (0.87–1.48)             | 0.88 (0.69–1.12)   | 1.11 (0.81–1.52)                   |
| Hormonal (n = 2,150) | ref                             | 1.28 (0.98–1.67)             | 1.06 (0.82–1.36)   | 1.26 (0.91–1.74)                   |
| Urinary incontinence (n = 2,310) | ref | 0.89 (0.68–1.16) | 0.91 (0.71–1.17)   | 0.75 (0.53–1.00)                   |
| Urinary irritation and obstruction (n = 2,239) | ref | 1.34 (1.04–1.74) | 1.11 (0.87–1.41)   | 1.19 (0.88–1.60)                   |
| **Medical history**  |                                 |                              |                    |                                     |
| Sexual (n = 2,355)   | ref                             | 1.43 (1.09–1.88)             | 0.97 (0.75–1.26)   | 0.60 (0.44–0.83)                   |
| Bowel (n = 2,316)    | ref                             | 1.18 (0.90–1.54)             | 0.89 (0.69–1.13)   | 1.15 (0.84–1.58)                   |
| Hormonal (n = 2,150) | ref                             | 1.35 (1.03–1.77)             | 1.08 (0.84–1.39)   | 1.32 (0.95–1.83)                   |
| Urinary incontinence (n = 2,310) | ref | 0.90 (0.69–1.18) | 0.90 (0.70–1.16)   | 0.73 (0.54–1.00)                   |
| Urinary irritation and obstruction (n = 2,239) | ref | 1.34 (1.03–1.74) | 1.10 (0.87–1.41)   | 1.18 (0.87–1.59)                   |

EPIC-26 = Expanded Prostate Index Composite—26; OR = odds ratio; ref = reference.

*Adjusted for sociodemographics (age [categorical], marital status, neighborhood education, neighborhood income, and primary language).

†Adjusted for sociodemographics and health status (body mass index and tobacco use).

‡Adjusted for sociodemographics, health status and medical history (Charlson comorbidity index, family history of prostate cancer, Gleason score, serum prostate-specific antigen level, and knowledge of prostate cancer status).

\( ^{a} P < .05; ^{b} P < .01; ^{c} P < .001 \)

CI = 0.44–0.83 compared with non-Hispanic white men. No interactions of race and ethnicity with any of the selected covariates were found to be statistically significant (data not shown).

**DISCUSSION**

We found few, relatively minor differences, apart from sexual function, in HRQOL before prostate cancer treatment across racial and ethnic subgroups. Overall, the sexual function domain had the lowest reported median scores (range = 50.0–62.5, maximum = 100.0) compared with the other four HRQOL domains (range = 87.5–100.0, maximum = 100.0). This is consistent with prior literature, attributing most of these low scores on the sexual function domain to the generally older age of men diagnosed with prostate cancer. We also found median scores on the urinary irritation and obstruction domain to be slightly lower than those seen on the urinary incontinence domain. This minor difference between urinary incontinence and urinary irritation has been identified in other investigations, regardless of the HRQOL questionnaire that was implemented. This suggests that many men might view the discomfort associated with urinary irritation and obstruction as more compromising than the inconvenience or embarrassment of bladder leakage.

In the fully adjusted multiple logistic regression models, one of the most significant findings was that men who identified as Asian or Pacific Islander were less likely to be above the median on the sexual function domain compared with their non-Hispanic white male counterparts. This finding has been identified in a previous study showing lower scores for Japanese and Japanese-American men before prostate cancer treatment on the sexual function domain compared with their non-Hispanic white men. One possible explanation for this finding might be the presence of a cultural barrier. It has been reported that Asian men might view engaging in health-seeking behavior as a loss of status or...
control that could damage their masculine identity. Therefore, these men might have accepted their sexual dysfunction as a natural part of aging and were less likely to seek treatment to address their poor sexual function.

Our findings also indicated non-Hispanic black men were more likely to be above the sample median on the sexual function, hormonal, and urinary irritation and obstruction domains compared with non-Hispanic white men. Although prior literature on racial and ethnic differences in HRQOL is limited, within the existing literature the HRQOL findings in non-Hispanic black men are varied. Some studies have shown that non-Hispanic black men report having worse HRQOL compared with non-Hispanic white men when evaluated at prostate cancer diagnosis and/or during post-treatment. Other studies have shown that psychosocial and HRQOL factors are better in non-Hispanic black men compared with non-Hispanic white men at prostate cancer diagnosis and during early treatment. These conflicting findings highlight the need for more prospective and longitudinal studies in non-Hispanic black men to elucidate some of the reasons for these HRQOL changes and to better understand those who maintain a stable HRQOL throughout the course of prostate cancer care.

Despite the numerous strengths of the present investigation, several potential limitations should be acknowledged. First, subtle domain differences might have been missed because of the decision to dichotomize at the median for each of the outcome variables (the five EPIC-26 domain scores). This decision was based on the high clustering of data on each of the outcome variables. When the dichotomization cut-point was moved to the 75th percentile, the findings were similar (data not shown), suggesting that this is likely not the case. Second, residual confounding could have occurred within our analyses. For example, we could not assess the clinical stage of the prostate cancer because of the large percentage of missing data. Therefore, this information was not included as a covariate in our analyses, but we did include covariates for Gleason score and PSA level to account for some prognostic factors of prostate cancer. Third, men included in our analyses completed the EPIC-26 HRQOL questionnaire after prostate biopsy diagnosis, which could have biased our findings. However, after performing sensitivity analysis that excluded those individuals who underwent a prostate biopsy examination before completing the EPIC-26 questionnaire, our results were unchanged (data not shown). Fourth, we could not account for individual-level income or education, which can influence HRQOL, but we did include covariates for neighborhood-level income and education. Fifth, generalizability could be limited because our population was composed of health-insured members. However, with the recent implementation of the Patient Protection and Affordable Care Act, these findings might be more representative of future racial and ethnic HRQOL differences. Sixth, although the EPIC-26 is a validated questionnaire of HRQOL in individuals diagnosed with prostate cancer, there are HRQOL domains that were not included in this questionnaire. Some of these domains include emotional well-being and anxiety that have been shown to be useful for individuals with prostate cancer. However, one of the goals of the initial investigation was to assess the feasibility of routine HRQOL screening within a clinical practice. The EPIC-26 HRQOL questionnaire, being brief and manageable, supports the idea of lessening provider and patient burden and encouraging participant completion.

In all, knowledge of pretreatment HRQOL differences by population subgroups is important for informing the prostate cancer care decision-making process. Targeted improvements in HRQOL, particularly for men who might have initially low pretreatment HRQOL, could lead to (i) a more effective selection of a course of prostate cancer treatment that minimizes specific HRQOL concerns, (ii) improved accuracy in the monitoring of any changes in HRQOL throughout the course of prostate cancer care, and (iii) the ability to set target goals and improvements in HRQOL during the prolonged survivorship period that is typically seen for individuals diagnosed with prostate cancer.

CONCLUSIONS

These findings suggest that, within an integrated health care organization, minimal racial and ethnic differences exist in pre-treatment HRQOL in men newly diagnosed with prostate cancer apart from sexual function. This finding provides important insight with which to interpret HRQOL changes during and after prostate cancer treatment for men newly diagnosed with prostate cancer.

Corresponding Author: Steven J. Jacobsen, MD, PhD, Department of Research and Evaluation, Kaiser Permanente Southern California, 100 S Los Robles Avenue, 2nd Floor, Pasadena, CA 91101, USA. Tel: 626-564-3478; fax: 626-564-3409; E-mail: Steven.J.Jacobsen@kp.org

Conflicts of Interest: The authors report no conflicts of interest.

Funding: This study was financially supported in part by a research grant from Intuitive Surgical, Inc.

Disclaimer: Although the company had the opportunity to comment on the written report, the Kaiser Permanente Southern California investigators had the final responsibility for all created content. All data were generated and analyzed at the Kaiser Permanente Southern California’s Department of Research and Evaluation.

STATEMENT OF AUTHORSHIP

Category 1

(a) Conception and Design
Stephanie R. Reading; Kimberly R. Porter; Jeffrey M. Slezak; Teresa N. Harrison; Joy S. Gelfond; Gary W. Chien; Steven J. Jacobsen

(b) Acquisition of Data
Stephanie R. Reading; Kimberly R. Porter; Jeffrey M. Slezak; Teresa N. Harrison; Joy S. Gelfond; Gary W. Chien; Steven J. Jacobsen
(c) Analysis and Interpretation of Data
Stephanie R. Reading; Kimberly R. Porter; Jeffrey M. Slezk; Teresa N. Harrison; Joy S. Gelfond; Gary W. Chien; Steven J. Jacobsen

Category 2
(a) Drafting the Article
Stephanie R. Reading; Kimberly R. Porter; Jeffrey M. Slezk; Teresa N. Harrison; Joy S. Gelfond; Gary W. Chien; Steven J. Jacobsen
(b) Revising It for Intellectual Content
Stephanie R. Reading; Kimberly R. Porter; Jeffrey M. Slezk; Teresa N. Harrison; Joy S. Gelfond; Gary W. Chien; Steven J. Jacobsen

Category 3
(a) Final Approval of the Completed Article
Stephanie R. Reading; Kimberly R. Porter; Jeffrey M. Slezk; Teresa N. Harrison; Joy S. Gelfond; Gary W. Chien; Steven J. Jacobsen

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Skolarus TA, Wolf AM, Erb NL, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64:225-249.
3. Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psychooncology 2002;11:307-326.
4. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-1261.
5. Jeldres C, Cullen J, Hurwitz LM, et al. Prospective quality-of-life outcomes for low-risk prostate cancer: active surveillance versus radical prostatectomy. Cancer 2015;121:2465-2473.
6. Alibhai SM, Brennis H, Timilshina N, et al. Long-term impact of androgen-deprivation therapy on physical function and quality of life. Cancer 2015;121:2350-2357.
7. Chipman JJ, Sanda MG, Dunn RL, et al; PROST-QA Consortium. Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. J Urol 2014;191:638-645.
8. Miller DC, Sanda MG, Dunn RL, et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005;23:2772-2780.
9. Gilbert SM, Dunn RL, Wittmann D, et al. Quality of life and satisfaction among prostate cancer patients followed in a dedicated survivorship clinic. Cancer 2015;121:1484-1491.
10. Davis KM, Kelly SP, Luta G, et al. The association of long-term treatment-related side effects with cancer-specific and general quality of life among prostate cancer survivors. Urology 2014;84:300-306.
11. Song L, Ji Y, Nielsen ME. Quality of life and health status among prostate cancer survivors and noncancer population controls. Urology 2014;83:658-663.
12. Quinten C, Martelli F, Coens C, et al; Patient Reported Outcomes and Behavioral Evidence (PROBE) and the European Organization for Research and Treatment of Cancer (EORTC) Clinical Groups. A global analysis of multiracial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer 2014;120:302-311.
13. Resnick MJ, Barocas DA, Morgans AK, et al. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: defining the population at risk for harms of prostate cancer treatment. Cancer 2014;120:1263-1271.
14. Glass AS, Cowan JE, Fuldeore MJ, et al. Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology 2013;82:60-65.
15. Ramsey SD, Zeliadt SB, Hall JJ, et al. On the importance of race, socioeconomic status and comorbidity when evaluating quality of life in men with prostate cancer. J Urol 2007;177:1992-1999.
16. Jayadevappa R, Johnson JC, Chhatre S, et al. Ethnic variation in return to baseline values of patient-reported outcomes in older prostate cancer patients. Cancer 2007;109:2229-2238.
17. Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med 2002;162:1985-1993.
18. Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in translation. Washington, DC: National Academies Press; 2006.
19. Gordon NP. How does the adult Kaiser Permanente membership in northern California Compare with the larger community? Oakland, CA: Kaiser Permanente Division of Research; 2006.
20. Koebnick C, Langer-Gould AM, Gould MK, et al. Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data. Perm J 2012;16:37-41.
21. Derose SF, Contreras R, Coleman KJ, et al. Race and ethnicity data quality and imputation using U.S. Census data in an integrated health system: the Kaiser Permanente Southern California experience. Med Care Res Rev 2013;70:330-345.
22. Szymanski KM, Wei JT, Dunn RL, et al. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 2010;76:1245-1250.
23. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
24. Thomas AA, Zheng C, Jung H, et al. Extracting data from electronic medical records: validation of a natural language processing program to assess prostate biopsy results. World J Urol 2014;32:99-103.
25. Bhattasali O, Chen LN, Woo J, et al. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat Oncol 2014;9:52.

26. Pinkawa M, Fischedick K, Gagel B, et al. Impact of age and comorbidities on health-related quality of life for patients with prostate cancer: evaluation before a curative treatment. BMC Cancer 2009;9:296.

27. Sood S, Ju AW, Wang H, et al. Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer. Radiat Oncol 2013;8:197.

28. Namiki S, Carlile RG, Namiki TS, et al. Racial differences in sexuality profiles among American, Japanese, and Japanese American men with localized prostate cancer. J Sex Med 2011;8:2625-2631.

29. Ho CC, Singam P, Hong GE, et al. Male sexual dysfunction in Asia. Asian J Androl 2011;13:537-542.

30. Lubeck DP, Kim H, Grossfeld G, et al. Health related quality of life differences between black and white men with prostate cancer: data from the cancer of the prostate strategic urologic research endeavor. J Urol 2001;166:2281-2285.

31. Penedo FJ, Dahn JR, Shen BJ, et al. Ethnicity and determinants of quality of life after prostate cancer treatment. Urology 2006;67:1022-1027.

32. Halbert CH, Coyne J, Weathers B, et al. Racial differences in quality of life following prostate cancer diagnosis. Urology 2010;76:559-564.

33. Nelson CJ, Balk EM, Roth AJ. Distress, anxiety, depression, and emotional well-being in African-American men with prostate cancer. Psychooncology 2010;19:1052-1060.

34. Ketchandji M, Kuo YF, Shahinian VB, et al. Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc 2009;57:24-30.